Warning: Declaration of MyAuthPlugin::initUser(&$user) should be compatible with AuthPlugin::initUser(&$user, $autocreate = false) in /home/tig/www/aalf/www/wiki/extensions/DDNAuthPlugin.php on line 37
Warning: session_name(): Cannot change session name when session is active in /home/tig/www/aalf/www/wiki/includes/Setup.php on line 222
Warning: session_set_cookie_params(): Cannot change session cookie parameters when session is active in /home/tig/www/aalf/www/wiki/includes/GlobalFunctions.php on line 2446
Warning: session_cache_limiter(): Cannot change cache limiter when session is active in /home/tig/www/aalf/www/wiki/includes/GlobalFunctions.php on line 2451
Warning: Parameter 1 to MediaWiki_TIGAutoAuthenticate() expected to be a reference, value given in /home/tig/www/aalf/www/wiki/includes/Hooks.php on line 117
Warning: Cannot modify header information - headers already sent by (output started at /home/tig/www/aalf/www/wiki/extensions/DDNAuthPlugin.php:4) in /home/tig/www/aalf/www/wiki/includes/Feed.php on line 125
Warning: Cannot modify header information - headers already sent by (output started at /home/tig/www/aalf/www/wiki/extensions/DDNAuthPlugin.php:4) in /home/tig/www/aalf/www/wiki/includes/WebResponse.php on line 10
Warning: Cannot modify header information - headers already sent by (output started at /home/tig/www/aalf/www/wiki/extensions/DDNAuthPlugin.php:4) in /home/tig/www/aalf/www/wiki/includes/WebResponse.php on line 10
Warning: Cannot modify header information - headers already sent by (output started at /home/tig/www/aalf/www/wiki/extensions/DDNAuthPlugin.php:4) in /home/tig/www/aalf/www/wiki/includes/WebResponse.php on line 10
Warning: Cannot modify header information - headers already sent by (output started at /home/tig/www/aalf/www/wiki/extensions/DDNAuthPlugin.php:4) in /home/tig/www/aalf/www/wiki/includes/WebResponse.php on line 10
Warning: Cannot modify header information - headers already sent by (output started at /home/tig/www/aalf/www/wiki/extensions/DDNAuthPlugin.php:4) in /home/tig/www/aalf/www/wiki/includes/WebResponse.php on line 10 DufourDeloach980 - Revision history
http://www.aalf.org/wiki/index.php?title=DufourDeloach980&action=history
Revision history for this page on the wikienMediaWiki 1.13.3Wed, 04 Nov 2026 06:42:13 GMTDufourDeloach980: New page: Tadalafil is a PDE5 inhibitor, currently marketed in pill form for treating erectile dysfunction (ED) under the name Cialis; and under the name Adcirca for the treatment of pulmonary arter...
http://www.aalf.org/wiki/index.php?title=DufourDeloach980&diff=46281&oldid=prev
<p>New page: Tadalafil is a PDE5 inhibitor, currently marketed in pill form for treating erectile dysfunction (ED) under the name Cialis; and under the name Adcirca for the treatment of pulmonary arter...</p>
<p><b>New page</b></p><div>Tadalafil is a PDE5 inhibitor, currently marketed in pill form for treating erectile dysfunction (ED) under the name Cialis; and under the name Adcirca for the treatment of pulmonary arterial hypertension. It initially was developed by the biotechnology company ICOS, and then again developed and marketed world-wide by Lilly ICOS, LLC, the joint venture of ICOS Corporation and Eli Lilly and Company. Cialis tablets, in 5 mg, 10 mg, and 20 mg doses, are yellow, film-coated, and almond-shaped. [http://manningmarketing.com cheap viagra] The approved dose for pulmonary arterial hypertension is 40 mg (two 20-mg tablets) once daily.<br />
Tadalafil is also manufactured and sold under the name of Tadacip by the Indian pharmaceutical company Cipla in doses of 10 mg and 20 mg.<br />
On November 21, 2003 the Food and Drug Administration approved tadalafil (as Cialis) for sale in the United States as the third ED prescription drug pill (after sildenafil citrate (Viagra) and vardenafil (Levitra)). [http://manningmarketing.com seo services canada] Cialis's 36-hour effectiveness earned it the nickname, "The Weekend Pill"; like sildenafil and vardenafil, tadalafil is recommended as an 'as needed' medication. Cialis is the only one of the three that is also offered as a once-daily medication.<br />
Moreover, tadalafil was approved in May 2009 in the United States for the treatment of pulmonary arterial hypertension and is currently under regulatory review in other regions for this condition. In late November 2008, [http://manningmarketing.com seo services canada] Eli Lilly sold the exclusive rights to commercialize tadalafil for pulmonary arterial hypertension in the United States to United Therapeutics for an upfront payment of $150 million.</div>Sat, 07 Apr 2012 18:18:43 GMTDufourDeloach980http://www.aalf.org/wiki/index.php?title=Talk:DufourDeloach980